AZ-BLUE-YONDER
Focused on empowering retailers to meet and exceed the rapidly evolving consumer expectations around fulfillment speed, convenience and accuracy, and to reduce the cost to fulfill, Blue Yonder has launched several microservices under the Luminate™ Commerce portfolio to help retailers meet the demands of consumers. These individually deployable, augmentative microservices offer a reimagined and personalized consumer experience by allowing retailers to ensure order and fulfillment accuracy.
E-commerce was rapidly growing prior to 2020; however, the COVID-19 pandemic pushed even more consumers online, contributing an additional $105 billion in U.S. online revenue in 2020 and accelerating e-commerce by two years , as reported in Digital Commerce 360 . In addition, nearly $1 in every $5 spent on retail purchases continue to come from digital orders , according an analysis of Commerce Department Q2 2021 data.
“The traditional monolithic solutions are very limiting to retailers and don’t give them the ability to add new features. Our microservices allow retailers to augmentatively add new capabilities without the need to rip and replace their existing solutions. This allows them to realize the value of the new capabilities quickly and meet business goals. As a result, many of our customers start with one microservice and after seeing benefits, they come back to us to implement additional services to help them meet customer demands while also keeping an eye on their bottom line,” said Eugene Amigud, corporate vice president, Product Management and Architecture, Blue Yonder.
Whether curbside pickup, buy online pickup in store (BOPIS), shipped from/to store, or same-day delivery/last-mile, retailers need omni-channel solutions to help them digitally transform to meet e-commerce growth. That’s why Blue Yonder has launched an end-to-end suite of highly scalable and individually deployable digital commerce microservices that include:
- Commits : Retailers can provide accurate, aggressive, and cost-effective promised delivery dates, and flexible fulfillment options early in the buying process to increase conversion rates, as well as optimize fulfillment to save costs. It enables retailers to deliver the right product, at the right time, through the consumers’ channel of choice, with the speed and convenience that consumers expect.
- Inventory Availability : Everyone needs to know where inventory is located and how it can be used. Retailers can present shoppers with enterprise-wide, real-time inventory availability data to incent them to buy. Retailers can show shoppers what’s available at their local store versus available for shipping and incent them to buy with urgency messaging (for example, one item left). Consumers can also easily reserve and then later buy products.
- Order Fulfillment : Retailers can perform store micro-fulfillment activities, i.e., pick, pack and fulfill orders, with increased accuracy and improved productivity. Store associates can serve customers thru various methods such as curbside delivery, deliver at home, delivery in-store, or ship to home. Store associates and managers have complete visibility of all store micro-fulfillment activities with actionable dashboards.
- Order Services and Customer Order Visibility (COV) – This high-performing, scalable API-based microservice orchestrates and manages the entire order-to-cash lifecycle. It provides a centralized view of orders, whether they are placed from a retailer’s website, a physical store, an online marketplace or a call center — and across brands and geographies. Customer Order Visibility (COV) is a real-time tracking and monitoring solution with an intuitive user experience that enables customer service, retail and other staff to search, view and modify real-time order details in one place, creating a single, up-to-date repository of order information. The COV uses an integrated user interface so businesses can search, view and modify order details in one place, with complete visibility into each order and its fulfillment details. Leveraging unsupervised learning algorithms, COV generates actionable insights on metrics that organizations can use to optimize the promising and fulfillment process.
Powered by machine learning analytics, these microservices can quickly detect anomalies with minimal or no manual configuration and draw attention to areas of potential need, including stock out predictions, sell through rates, the need for markdowns, and inventory accuracy.
“Our microservices enable retailers to leverage stores in their digital transformation journey while continuing to manage existing day-to-day operations. Retailers can now empower today’s shoppers to make smarter decisions, increasing customer satisfaction while streamlining store fulfillment operations and increasing productivity and revenue,” said Omar Akilah, corporate vice president – Commerce, Blue Yonder.
Additional Resources:
- Learn more about how Blue Yonder’s new microservices provide a personalized commerce experience
- At NRF 2022 Retail’s Big Show in New York City, join the “Smarter customer connections at Petco and Sally Beauty produced by Blue Yonder” Big Ideas session on Jan. 17, 2022, 10:15 a.m. ET
- Learn more about Blue Yonder’s Luminate Commerce portfolio
- Learn more about intelligent order promising
- Watch the “Journey of the Yoga Pants with Luminate Commerce” video
About Blue Yonder
Blue Yonder is the world leader in digital supply chain and omni-channel commerce fulfillment. Our intelligent, end-to-end platform enables retailers, manufacturers and logistics providers to seamlessly predict, pivot and fulfill customer demand. With Blue Yonder, you can make more automated, profitable business decisions that deliver greater growth and re-imagined customer experiences. Blue Yonder - Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118005129/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
